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Abstract: Pancreatic cancer is one of the most lethal malignancies with poor prognosis. 
Previously,  we  found  that  a  subpopulation  of  cancer  stem  cells  (CSCs)  in  the  Panc-1 
pancreatic cancer cell line could propagate to form spheres. Here we characterized the 
malignant  phenotypes  of  the  pancreatic  cancer  stem  CD44+/CD24+  cells,  which  were 
enriched  under  sphere  forming  conditions  as  analyzed  by  flow  cytometry.  These  cells 
demonstrated  increased  resistance  to  gemcitabine  and  increased  migration  ability. 
Moreover, these cells exhibited epithelial to mesenchymal transition characterized by a 
decreased  level  of  the  epithelial  marker  E-cadherin  and  an  increased  level  of  the 
mesenchymal marker vimentin. Notably, abnormal expression of Bmi-1, ABCG2, Cyclin 
D1 and p16 were found in Panc-1 CSCs. Our results suggest that targeted inhibition of 
CSCs represents a novel therapeutic approach to overcome chemoresistance and metastasis 
of pancreatic cancer. 
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1. Introduction 
Pancreatic  cancer  is  currently  the  fourth  leading  cause  of  cancer-related  mortality  in  Western 
countries. Despite advances in tumor biology and the development of cancer therapeutic strategies, the 
prognosis of pancreatic cancers remains miserable, with the five year survival rate less than 5% [1]. 
The poor prognosis of pancreatic cancer is mainly attributed to the malignant behavior of pancreatic 
cancer. Extensive local invasion and early systemic dissemination are hallmarks of pancreatic cancer. 
Moreover,  pancreatic  cancer  is  resistant  to  most  cytotoxic  drugs.  The  high  recurrence  rate  after 
operation remains a big problem for clinicians. 
The discovery of cancer stem cells (CSCs) has changed our view of carcinogenesis and cancer 
therapy. It is proposed that subgroups of cancer stem cells within the tumor sustain the formation and 
growth of the tumor and account for tumor recurrence due to their self-renewal and differentiation 
abilities, metastatic potential, and resistance to conventional therapeutics [2–4]. Cancer stem cells have 
been identified and isolated from a variety of cancers including the blood, breast and central nervous 
system and pancreas cancers [5–9]. Thus, further characterization of pancreatic cancer stem cells may 
improve the prognosis and therapy of pancreatic cancer. 
In a previous study, we found that a subpopulation of cells in the Panc-1 pancreatic cancer cell line 
could propagate to form spheres, and strikingly these cells exhibit features of CSCs such as extensive 
self-renewal, proliferation, differentiation, and tumorigenesis [10]. On this basis, we went further to 
characterize the malignant phenotypes of these pancreatic cancer stem cells such as chemoresistance 
and motility and investigate the potential mechanisms responsible for these phenotypes. 
2. Results and Discussion 
2.1. CSC Population of Panc-1 Cells Is Enriched under Sphere-Forming Conditions 
Cell surface markers have been widely used to isolate stem cells. The surface markers CD44, CD24, 
and ESA have been well defined for isolating CSCs from primary pancreatic adenocarcinomas [9]. The 
CD44+/CD24+  subpopulation  isolated  from  Panc-1  cells  was  considered  to  consist  of  pancreatic 
cancer cells with stem cell properties due to their increased in vitro clonogenic and in vivo tumor 
initiating potential [11]. By flow cytometry analysis, we found that the CD44+/CD24+ subpopulation 
of cells accounted for 12.6 ±  5.10% in the Panc-1 CSC group but only accounted for 1.43 ±  0.59% in 
Panc-1  cells  (Figure  1).  These  results  indicated  that  the  pancreatic  cancer  cells  with  stem  cell 
properties were enriched under sphere forming conditions. 
2.2. Panc-1 CSCs Exhibit Increased Chemoresistance to Gemcitabine 
As the first step to characterize the phenotypes of the pancreatic CSCs, we sought to determine their 
chemosensitivity.  Both  Panc-1  cells  and  Panc-1  CSC  were  exposed  to  the  most  widely  used 
chemotherapeutic agent: gemcitabine. The cell viability was determined by MTT assay and the results 
demonstrated that while Gemcitabine inhibited the proliferation of Panc-1 cells and Panc-1 CSC in a 
dose dependent manner, Panc-1 CSCs showed a relative resistance to gemcitabine compared to Panc-1 
cells cultured in monolayer, and the difference between the growth inhibition rate of these two groups Int. J. Mol. Sci. 2011, 12                       
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was statistically significant (P < 0.05) (Figure 2). These data demonstrate that Panc-1 CSCs exhibit 
increased resistance to gemcitabine compared to Panc-1 cancer cells. 
Figure  1. The Panc-1 cell cancer stem cell (CSC) subpopulation (CD44+/CD24+) was 
enriched under sphere-forming conditions. The right upper quadrant (Q2-2) indicates the 
distribution of the CD44+/CD24+ subgroup of cells as analyzed by flow cytometry. The 
experiment was repeated 5 times and the data are expressed as mean ±  standard deviation, 
statistically  significant  differences  were  determined  by  Student’s  t  test,  the  difference 
between the Panc-1 group and the Panc-1 CSC group was significant, p < 0.05. 
 
Figure 2. Panc-1 CSCs have increased chemoresistance to gemcitabine. Panc-1 CSCs or 
Panc-1 cells were treated with various dosages of gemcitabine for 48 h. Cell viability was 
determined  by  MTT  assay.  Panc-1  CSCs  showed  increased  resistance  to  gemcitabine 
compared to Panc-1 cells cultured in monolayer.  
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2.3. Panc-1 CSCs Exhibit Increased Migration Ability 
Recent  evidence  suggests  that  CSCs  may  drive  the  progression  and  metastasis  of  malignant  
cancer [12]. Since metastasis depends on increased motility of cancer cells, we examined the migration 
ability of Panc-1 CSCs by transwell migration assay. It was observed that larger numbers of Panc-1 
CSCs migrated to the lower side of the membrane compared to Panc-1 cells (Figure 3), suggesting that 
Panc-1 CSCs have increased migration ability. Int. J. Mol. Sci. 2011, 12                       
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Figure 3. Panc-1 CSCs have increased migration ability. The migration of Panc-1 CSCs or 
Panc-1 cells was determined by transwell migration assay. After the filter was fixed and 
stained, the number of cells migrated to the undersurface of the filter was compared. Left 
side: Panc-1 CSCs had increased migration ability compared to Panc-1 cells, (40×  fold).  
* p < 0.05. Right side: images of Panc-1 cells (top) and Panc-1 CSCs (bottom). 
 
2.4. Panc-1 CSCs Exhibit Epithelial to Mesenchymal Transition (EMT) 
Tumor  metastasis  is  often  correlated  with  loss  of  epithelial  properties  and  acquisition  of  the  
fibroblast-like  phenotype  of  cancer  cells,  a  phenomenon  known  as  EMT  [13].  Thus,  we  further 
investigated  whether  the  increased  motility  of  Panc-1  CSCs  results  from  EMT.  By  Western  blot 
analysis we found that the protein level of the epithelial marker E-cadherin was decreased, and that of 
the  mesenchymal  marker  vimentin  increased  in  Panc-1  CSCs  compared  with  Panc-1  cancer  cells 
(Figure 4), indicating that Panc-1 CSC had undergone EMT. 
Figure 4. Panc-1 CSCs demonstrate a phenotype suggestive of epithelial to mesenchymal 
transition (EMT). The expression levels of E-cadherin and vimentin in Panc-1 CSCs and 
Panc-1  cells  were  determined  by  Western  blot  analysis  (left).  Densitometry  analysis 
revealed the differences between Panc-1 CSCs and Panc-1 cells (right). * p < 0.05. 
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2.5. Abnormal Expression of Bmi-1, ABCG2, Cyclin D1 and p16 in Panc-1 CSCs 
We further explored the possible mechanisms responsible for the malignant phenotypes of Panc-1 
CSCs  as  shown  above.  Multidrug  resistance  is  an  important  mechanism  for  pancreatic  cancer  to 
acquire chemoresistance and ATP-binding cassette (ABC) transporters participate in pumping the drug 
out of the cancer cells and endowing multidrug resistance. By Western blot analysis, we found that 
ABCG2/BCRP1 was overexpressed in Panc-1 CSCs compared to Panc-1 cells. In addition, Cyclin D1, 
an important regulator of cell cycle progression and proliferation, was overexpressed in Panc-1 CSCs. 
p16,  one  of  the  important  regulators  of  cellular  senescence  and  apoptosis,  was  downregulated  in  
Panc-1 CSCs. Bmi-1, which is an oncogene and stem cell renewal factor, was also highly expressed in 
Panc-1 CSCs (Figure 5). 
Figure 5. Abnormal expression of Bmi-1, ABCG2, Cyclin D1 and p16 in Panc-1 CSCs. 
The levels of Bmi-1, ABCG2 and p16 in Panc-1 CSCs and Panc-1 cells were determined 
by Western blot analysis and normalized to GAPDH (left). Densitometry analysis revealed 
the differences between Panc-1 CSCs and Panc-1 cells. * p < 0.05. 
 
2.6. Discussion 
The  cancer  stem  cell  theory  posits  that  a  small  population  of  progenitors  with  extensive  
self-renewal  properties  determines  the  initiation  and  behavior  of  tumors.  Mounting  evidence  has 
demonstrated  the  important  role  that  cancer  stem  cells  play  in  tumor  initiation,  maintenance, 
progression and recurrence [14]. Moreover, cancer stem cells display increased resistance to apoptosis 
induced  by  cytotoxic  agents  and  radiation  therapy  [15].  The  intrinsic  resistance  to  apoptosis  may 
endow CSCs with chemoresistant ability. In the present study, we found that Panc-1 CSCs showed 
increased  resistance  to  commonly  used  chemotherapeutic  drugs  compared  to  Panc-1  cells.  These 
results validate the point that current therapies might target the bulk of the tumor, but the resistant 
cancer stem cells may be enriched and rapidly repopulate the tumor from which they originated after 
chemotherapy [16]. As for pancreatic cancer, the resistant cancer stem cells may be the origin of 
recurrence after chemotherapy and measures to eradicate these cells may be crucial for improving the 
prognosis of pancreatic cancer. 
We further explored the possible mechanisms by which the resistance to chemotherapy may be 
regulated in Panc-1 CSCs. The epigenetic regulator Bmi-1 belongs to the polycomb group family, 
which plays essential roles in the self-renewal and propagation of normal and cancer stem cells [17]. In Int. J. Mol. Sci. 2011, 12                       
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many cases, Bmi-1 functions as an oncogene and endows the cancer cells with strong antiapoptotic 
properties  via  dysregulation  of  multiple  mechanisms  [18].  Moreover,  Bmi-1  is  up-regulated  in 
pancreatic cancer and this is related to the poor prognosis of pancreatic cancer patients [19]. In our 
study,  Bmi-1  is  expressed  at  high  levels  in  Panc-1  CSCs  compared  to  Panc-1  cells  cultured  in 
monolayer. This indicated that Bmi-1 may not only contribute to maintain the cancer stem cells in 
pancreatic cancer, but will also endow abnormal growth and chemoresistant ability to the CSCs. 
Interestingly, we found that the expression of the ABC transporter ABCG2 was increased in Panc-1 
CSCs compared to Panc-1 cells cultured in monolayer. ABCG2 belongs to the ABC transporter family, 
which protects cells by pumping a variety of cytotoxic agents out of the cells. This property endows 
the multidrug resistance to cancer cells and is a major obstacle to successful cancer chemotherapy [20]. 
Moreover, the drug-transporting property conferred by the ABCG2 transporter results in diminished 
intracellular  accumulation  of  Hoechst  33342,  accounting  for  the  increased  side  population  (SP) 
phenotype.  Indeed,  increased  ABCG2  expression  may  be  a  common  feature  of  pluripotent  stem  
cells [21]. In our study, increased expression of ABCG2 further verifies the stem cell properties of  
Panc-1 CSCs. 
Our  results  also  demonstrate  that  p16,  a  regulator  of  cell  senescence  and  cell  cycle,  was 
downregulated  in  Panc-1 CSCs.  Loss of  p16 function may be  involved in  the carcinogenesis and 
aggressive behavior of pancreatic cancer [22]. The downregulation of p16 in Panc-1 CSCs may explain 
the high propagation capacity of Panc-1 spheres cultured both in vitro and in vivo as demonstrated in 
our previous study [10]. p16 is also implicated in the apoptosis and chemotherapy of pancreatic cancer. 
In  many  cases,  p16  expression  has  been  used  to  determine  the  sensitivity  of  cancer  cells  to 
chemotherapy  and  adenoviral-mediated  p16INK4A  reintroduction  could  greatly  enhance  the 
cytotoxicity of 5-Fluorouracil or gemcitabine in Panc-1 pancreatic adenocarcinoma cells [23]. In our 
study, the downregulation of p16 in Panc-1 CSC may partly account for the resistance of Panc-1 CSCs 
to chemotherapy. 
Cyclin D1 is an important regulator of cell cycle progression. The overexpression of cyclin D1 has 
been linked to the development and progression of pancreatic cancer through promoting abnormal 
growth and resistance to chemotherapy [24,25]. Moreover, recently studies have revealed that cyclin 
D1  kinase  activity  is  required  for  the  self-renewal  of  mammary  stem  and  progenitor  cells  [26]. 
Therefore, our results indicate that high expression of cyclin D1 may help maintain and regulate the 
biology of cancer stem cells in Panc-1 cells and multiple mechanisms cooperate to contribute to the 
resistance of Pan-1 CSCs to chemotherapy. 
Recent evidence has supported the link of chemoresistance and EMT with stem cell phenotype [27]. 
EMT is known to promote the invasion and metastasis of tumors [28]. However, emerging lines of 
evidence  suggest  molecular  and  phenotypic  associations  between  apoptotic  resistance  and  the 
acquisition  of  an  EMT–like  phenotype  in  cancer  cells  [29,30].  In  our  experiments,  
Panc-1  CSCs  exhibited  increased  migration  ability  compared  to  Panc-1  cells  and  demonstrated 
downregulation  of  the  epithelial  marker  E-cadherin  and  upregulation  of  the  mesenchymal  marker 
vimentin. Thus, we conclude that Panc-1 CSCs undergo EMT. Considering the role EMT plays in 
invasiveness  and  dissemination  of  cancer,  such  features  may  facilitate  the  escape  of  the  resistant  
Panc-1 CSCs during chemotherapy. Int. J. Mol. Sci. 2011, 12                       
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3. Experimental Section 
3.1. Cell Lines and Cell Culture 
The pancreatic cancer cell line Panc-1 originated from ATCC (Manassas, VA, USA), and  was 
cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/mL pencillin and 100 U/mL 
streptomycin at 37 °C  with 5% CO2. The culture conditions for Panc-1 cells to form tumor spheres in 
suspension  was  as  described  previously  [10].  The  sphere  formation  media  (SFM)  used  was  
DMEM-F12  supplemented  with  10  ng/mL  fibroblast  growth  factor-basic  (Peprotech),  20  ng/mL 
epidermal growth factor (Peprotech), 5 µg/mL insulin, 2.75 µg/mL transferrin, 2.5 ng/mL sodium 
selenite (Sigma), and 0.4% bovine serum albumin (Amresco). Briefly, the enzymatically dissociated 
single cells were diluted to a density of 10
3 cells/mL with SFM, and plated into the low attached plate. 
The cells were passaged every 10 to 14 days and replated in the SFM. The spherical clusters of cells 
grown under these conditions were named Panc-1 CSCs. 
3.2. Flow Cytometry Assay 
Panc-1 cells were dissociated with trypsin-EDTA solution (trypsin, 0.25%; EDTA, 0.02%) and 
washed  twice  with  phosphate-buffered  saline  (PBS)  and  resuspended  in  PBS  at  a  density  of  
1 ×  10
6 cells/100 μL. The dissolved cells were stained using APC antihuman CD44, PE anti-human 
CD24 and ESA-FITC (Biolegend) at a dilution of 1:40, incubated for 20 min on ice and then washed 
twice  with  PBS.  The  respective  isotype  controls  were  used  at  concentrations  according  to  the 
manufacturer’s instruction. The samples were analyzed on a flow cytometer (BD LSRⅡ, America) 
and the data were analyzed with the BD FACS Diva software. 
3.3. MTT Cell Proliferation Assay 
Three groups were divided: blank group (no cells), control group (no treatment), experiment group 
(gemcitabine treatment). Cells were plated in 96 well plates with a density of 10,000 cells/well. 24 h 
later the cells were incubated with medium containing various concentration of gemcitabine (Eli Lilly) 
for 48 h. Then 5 mg/mL of 3-(4,5-dim ethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
(Sigma) was added to each well. After incubation for 4 h, the supernatant was replaced with 150 µL of 
dimethyl  sulfoxide (Sigma). The absorption (A) was read at 490 nm using a spectrophotometer. The 
inhibition  rate  of  cell  proliferation  was  calculated  as:  (Acontrol  −  Ablank)  −  (AexperimentAblank)/ 
(Acontrol − Ablank) ×  100%. The experiments were performed in triplicate and repeated twice. 
3.4. Transwell Migration Assay 
The  migration  assay  was  performed  using  transwell  cell  culture  chambers  (8  µM  pore  size 
polycarbonate  membrane,  Costar).  Briefly,  cells  were  resuspended  in  DMEM  with  1%  FBS  to  a 
concentration of 5 ×  10
5/mL. The upper chamber was loaded with 100 µL of cell suspension and the 
lower chamber was loaded with 600 µL of DMEM with 20% FBS. After incubation for 24 h at 37 °C  
with 5% CO2, the filter was fixed with 4% paraformaldehyde and stained with hemaroxylin. The cells 
on  the  upper  side  of  the  filter  were  wiped  off  with  a  cotton  swab.  The  cells  migrated  to  the Int. J. Mol. Sci. 2011, 12                       
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undersurface of the membrane were counted under microscope. Ten microscopic fields (400× ) were 
randomly selected to count cells. Each assay was done in triplicate. 
3.5. Western Blot Analysis 
Pancreatic  cancer  cells  were  lysed  in  lysis  buffer  (20  mM  Tris  pH  7.5,  150  mM  NaCl,  
1% Triton X-100, 0.1% NP40, 0.5% sodium deoxycholate, 1 mM of phenylmethylsulfonyl fluoride 
and gabexate mesilate). The protein concentration of the lysate was quantitated by BSA method. Equal 
amounts  of  lysate  were  loaded  and  separated  by  SDS-polyacrylamide  gels,  and  transferred  onto 
nitrocellulose membranes. The membranes were blocked with 5% non-fat milk powder in TBS for 1 h 
and probed with primary antibodies against vimentin (Sigma, 1:200 dilution), E-cadherin (Santa Cruz, 
1:500 dilution), p16 (Santa Cruz, 1:400 dilution), ABCG2 (Santa Cruz, 1:300 dilution) or GAPDH 
(ProMab, 1:8000 dilution). After washing with TBS-T, the membrane was incubated with secondary 
horseradish peroxidase-coupled antibodies and visualized using enhanced chemiluminescence.  
3.6. Statistical Analysis 
The differences between different groups were evaluated using the Student’s t test. P < 0.05 was 
considered significant. 
4. Conclusions 
In summary, our results indicate that cancer stem cells are enriched in Panc-1 spheres and they 
demonstrate an EMT phenotype and increased resistance to gemcitabine and motility. Overexpression 
of Bmi-1, ABCG2 and cyclin D1 and downregulation of p16 could contribute to these phenotypic 
changes of Panc-1 cancer stem cells. 
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